- Home
- KRON vs MURA Comparison
KRON vs MURA Comparison
Compare KRON & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- MURA
- Stock Information
- Founded
- KRON 2017
- MURA 2013
- Country
- KRON United States
- MURA Ireland
- Employees
- KRON N/A
- MURA N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- MURA
- Sector
- KRON Health Care
- MURA
- Exchange
- KRON Nasdaq
- MURA Nasdaq
- Market Cap
- KRON 41.5M
- MURA 45.8M
- IPO Year
- KRON 2020
- MURA N/A
- Fundamental
- Price
- KRON $0.87
- MURA $2.46
- Analyst Decision
- KRON Buy
- MURA Strong Buy
- Analyst Count
- KRON 3
- MURA 4
- Target Price
- KRON $1.63
- MURA $13.00
- AVG Volume (30 Days)
- KRON 1.4M
- MURA 106.6K
- Earning Date
- KRON 08-07-2025
- MURA 08-12-2025
- Dividend Yield
- KRON N/A
- MURA N/A
- EPS Growth
- KRON N/A
- MURA N/A
- EPS
- KRON N/A
- MURA N/A
- Revenue
- KRON $9,192,000.00
- MURA N/A
- Revenue This Year
- KRON N/A
- MURA N/A
- Revenue Next Year
- KRON N/A
- MURA N/A
- P/E Ratio
- KRON N/A
- MURA N/A
- Revenue Growth
- KRON 21.16
- MURA N/A
- 52 Week Low
- KRON $0.65
- MURA $0.95
- 52 Week High
- KRON $1.60
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- KRON 64.27
- MURA 44.84
- Support Level
- KRON $0.87
- MURA $2.51
- Resistance Level
- KRON $0.90
- MURA $2.66
- Average True Range (ATR)
- KRON 0.02
- MURA 0.09
- MACD
- KRON 0.01
- MURA -0.02
- Stochastic Oscillator
- KRON 87.65
- MURA 20.08
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.